Headlands Technologies LLC purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 18,161 shares of the company’s stock, valued at approximately $1,161,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $31,000. KBC Group NV acquired a new position in Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.
Kiniksa Pharmaceuticals International Stock Performance
Shares of NASDAQ KNSA opened at $78.63 on Tuesday. The firm has a market cap of $6.13 billion, a PE ratio of 81.06 and a beta of 0.05. The firm has a fifty day moving average of $70.32 and a 200 day moving average of $56.48. Kiniksa Pharmaceuticals International, plc has a one year low of $33.25 and a one year high of $82.94.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the company. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. JPMorgan Chase & Co. raised their price target on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. The Goldman Sachs Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Finally, Citigroup boosted their target price on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $87.38.
View Our Latest Stock Report on Kiniksa Pharmaceuticals International
Insiders Place Their Bets
In other news, Director G Bradley Cole sold 3,673 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 51.98% of the company’s stock.
Kiniksa Pharmaceuticals International Company Profile
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Free Report).
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
